BACKGROUND: Storage of red blood cells (RBCs) under blood bank conditions promotes metabolic modulation within the RBC. This "metabolic storage lesion" may affect the quality and safety of the transfused RBCs. The aim of this study is to determine the metabolic changes in stored RBCs over 42 days of routine storage followed by a US Food and Drug Administration-approved method of rejuvenation, freezing, and preparation for transfusion.
STUDY DESIGN AND METHODS:
We exploited a mass spectrometry-based metabolomics approach to monitor 42-day-stored citrate phosphate dextrose/AS-1 RBCs (n 5 29) that were rejuvenated, glycerolized and frozen, then thawed and deglycerolized, and held for 24 hours at 1 to 6 C in saline-glucose.
RESULTS: Previously reported metabolic alterations
were confirmed in 42-day-old RBCs. In this study, in total, 181 (62%) of the biochemical compounds exhibited significant (p 0.05) change compared with Day 0 values. Rejuvenation restored adenosine triphosphate and 2,3-diphosphoglycerate levels, replenished purine reservoirs, up regulated glycolysis, increased levels of pentose phosphate pathway intermediates, and partially rescued glutathione biosynthesis. Increased levels of lysophospholipid in rejuvenated RBCs suggests the activation of recycling pathways of damaged membrane lipids, in which a total of 167 (57%) biochemical compounds showed significant change compared with Day 42 values.
CONCLUSION:
Rejuvenation reversed over one-half of the metabolic biochemical compounds evaluated compared with Day 42 values, and the compounds were stable through frozen storage and preparation for transfusion. Rejuvenation promoted significant metabolic reprogramming, including the reactivation of energy-generating and antioxidant pathways (the pentose phosphate pathway and glutathione homeostasis), salvage reactions, cofactor reservoirs, and membrane lipid recycling.
E xtended, refrigerated storage of red blood cells (RBCs) is a logistic necessity that permits millions of units to be available for transfusion every year. Despite a century of progress in the field, 1 storage of RBCs under routine blood banking conditions can still be improved. 2 Indeed, observational studies published over the last decade have documented a long series of biochemical, physiological, and morphological alterations caused by hypothermic liquid storage conditions, a phenomenon collectively referred to as the "storage lesion." 3, 4 A deeper understanding of the complexity of the storage lesion is due to the recent introduction of the socalled "omics" technologies: analytical approaches targeting specific classes of biologic molecules, such as smallmolecule (<1.5 kDa) metabolites in metabolomics.
Metabolomics technologies have documented hundreds of metabolic changes to key energy and redox metabolic pathways in RBCs stored longer than 2 weeks in different additive solutions (AS), including saline-adenine-glucosemannitol (SAGM), [5] [6] [7] AS-1, 8 AS-3, 9 AS-5, 10 and, to a lesser extent, AS-7. 11 However, the field has been left wondering
whether and to what extent these metabolic changes correlate to the physiology and functionality of the stored RBCs and, ultimately, whether the metabolic storage lesion affects the safety and efficacy of the transfused RBC. [12] [13] [14] Although correlative and functional mechanistic studies have been solicited by leading experts in the field, 2 results from randomized clinical trials seem to suggest that RBC storage duration does not significantly compromise clinical outcomes for the majority of recipients. [15] [16] [17] The apparent disconnection between observational in vitro studies and evidence-based clinical observations may be justified by the reversibility of the majority of storage lesions in the bloodstream of the recipient upon transfusion. A recurring example is rapid depletion of the high-energy phosphate compounds adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (DPG), which are rescued after 8 to 72 hours after transfusion, as documented in classic studies. 18 A process known as biochemical modification or "rejuvenation" was originally developed as a process used to salvage outdated RBC concentrates. 19 24 Gelderman and Vostal have reported the effects of rejuvenation, when using the approved incubation method, on pump-induced physical and osmotic stress resistance of stored RBCs in an in vitro model. 25 Despite some inconsistencies in the potential effects of rejuvenation on morphological and rheological properties of stored RBCs, all studies performed to date have consistently documented a metabolic effect of rejuvenation in terms of replenished ATP and DPG levels. 26 Although additional metabolic effects of rejuvenation are expected, to the authors' knowledge, no comprehensive metabolomics analyses of rejuvenated RBCs have been performed so far. We hypothesize that the rejuvenation of 42-day-old RBCs promotes significant, systemic metabolic reprogramming beyond ATP and 2,3-DPG replenishment. Our aim is to determine the metabolic changes in stored RBCs over the course of a routine 42 days of refrigerated storage followed by an FDA-approved method of rejuvenation, freezing, and preparation for transfusion.
MATERIALS AND METHODS

Blood processing and sample collection
Healthy volunteers recruited from the local community provided informed consent for whole blood collection. Participants were at least 18 years of age and met all AABB and FDA requirements for blood donation, with the exception that travel restrictions were waived. The study was reviewed and approved by the Dartmouth Institutional Review Board and conformed to the Declaration of Helsinki. Whole blood (550 mL) was collected into citratephosphate-dextrose anticoagulant (CPD 4R1582; Fenwal, Inc.), component processed following standard procedures, 110 mL of ADSOL preservative solution (AS-1) was added to RBCs, leukocyte-reduced by filtration, placed at 1 to 68C within 8 hours of collection, and stored at 1 to 68C according to standard procedures for 42 days. Units were then rejuvenated, frozen, thawed, deglycerolized, and stored for 24 hours, as described below. Samples for standard hematology assays, targeted metabolomics, and metabolomics screening were aseptically obtained according to Table 1 .
Rejuvenation
On Day 42 of storage, 50 mL of Rejuvesol Red Blood Cell Processing Solution (PN 7012; Citra Labs) was added aseptically to each unit of RBCs using a Y-Type Rejuvenation Set (PN 7212; Citra Labs) with constant manual agitation ( Table 2 ). The Rejuvesol solution was double over-wrapped and incubated in a 37 6 18C water bath for 60 6 1 minutes with continuous mixing (Quick Thaw Plasma Thawing System, DH4; Helmer). The overwraps were removed, and the rejuvenated RBCs were centrifuged (3000 3 g for 7 minutes at 20-248C). The supernatant was transferred into the 250-mL transfer pack of the Y-Set and then discarded.
Glycerolization and freezing
Rejuvenated RBCs were glycerolized using Glycerolyte 57 Solution, 400 mL (Fenwal 4A7833 or 4A7831), to a final concentration of 40% weight/volume glycerol, in a special plastic freezing bag (Baxter 4R2422), enclosed in an aluminum freezing container, and frozen at or below 2658C by placing the freezing container in a mechanical chest freezer. The rejuvenated/frozen RBCs were stored at or below 2658C for at least 7 days.
Thawing, deglycerolization, and storage
The rejuvenated/frozen RBCs were thawed and warmed to approximately room temperature in a 37 6 18C water bath. RBCs were deglycerolized using the COBE 2991 Blood Cell Processor (Terumo BCT, Inc.) following the manufacturer's directions using a total of approximately 2.2 liters of processing solution. Briefly, RBCs were prediluted with 150 mL of 12% sodium chloride solution (Fenwal 4B7878) using manual agitation, followed by a 2-minute hold, then 300 to 500 mL of 1.6% sodium chloride solution (Fenwal 4B7871) was added with manual agitation and a 2-minute hold. The thawed-diluted RBCs were concentrated by centrifugation (1245 3 g for 4 minutes) in the blood cell processor, and the supernatant was discarded. The RBCs were washed once with approximately 500 mL of 1.6% sodium chloride and twice with approximately 450-mL volumes of 0.9% sodium chloride and 0.2% dextrose (saline/dextrose; Fenwal 4B7877). The RBCs were resuspended to a hematocrit of about 40% using 100 mL of saline/dextrose and then stored at 1 to 68C for up to 24 hours.
Hematology testing
Automated hematology testing was performed on the Sysmex XE2100D (Sysmex America). Spun hematocrits were determined using the Hettich Mikro 20 microhematocrit centrifuge (Hettich). Supernatants were prepared by double centrifugation at 2840 3 g for 10 minutes (Hettich Rotanta 460RS). Supernatant sodium and potassium concentrations were determined by ion-specific electrodes (PPE; Roche Diagnostics) and supernatant hemoglobin (Hb) using a Drabkin reagent method (Sigma) automated on the COBAS FARA (Roche) with a turbidity correction. Supernatant osmolality was measured by freezing point depression (Model 2020 Osmometer; Advanced Instruments). RBCs were prepared for targeted metabolomics assay by perchloric acid deproteinization, neutralization with 3M K 2 CO 3 , and freezing at 2808C until analysis. Perchloric acid extracts were analyzed for ATP using the NADP1 reduction method of Beutler automated for the COBAS FARA, 2,3-DPG (Roche Diagnostics) and for residual hypoxanthine and inosine using high-performance liquid chromatography.
Metabolomics extraction
One-milliliter aliquots for metabolic survey were frozen at 2808C and held until analyses. Metabolomics were performed as previously reported. 10 Samples were prepared using the automated MicroLab STAR system from Hamilton Company and were assayed by gas chromatographymass spectrometry and liquid chromatography tandemmass spectrometry platforms (either a Thermo-Finnigan Trace DSQ fast-scanning, single-quadrupole mass spectrometer using electron impact ionization or a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ-FT mass spectrometer), run either in positive or negative ion modes with adequate buffer, column, phase, and gradient 
Hct 5 hematocrit; MCV 5 mean corpuscular volume; fL 5 femtoliters; MCH 5 mean corpuscular hemoglobin; pg 5 picograms; MCHC 5 mean corpuscular hemoglobin concentration. adjustments. Compounds were identified by comparison with library entries of purified standards or recurrent unknown entities within a window range of 5 parts per million (Metabolon, Inc.). The relative metabolite concentration was calculated by imputation of any missing values present with the minimum observed value for each compound, normalization to Bradford protein concentration, and log transformation of median scaled data.
Statistical analysis
Repeated-measures analyses of variance relative metabolite concentrations were used to identify biochemicals that differed significantly between experimental treatment groups (significance threshold for p values < 0.05). The false-discovery rate was estimated using the q value, totally unsupervised principal component analysis, and partially supervised partial least square discriminant analysis (PLS-DA). Perchloric acid and PLS-DA values were calculated through the macro MultiBase (freely available at www.numericaldynamics.com). Hierarchical clustering analysis was performed with GENE-E software package (Broad Institute). 
RESULTS
Twenty-nine evaluable units were studied (Table 3 ). All units had less than 1% hemolysis at Day 42 of storage (pre-rejuvenation, 0.3 6 0.1%; maximum, 0.6%). Rejuvenation treatment did not increase the level of hemolysis. As expected, 27 hemolysis after the freeze/thaw process was 2.1 6 0.5%. After deglycerolization, however, the mean percentage hemolysis levels (0.4 6 0.2%) were similar to the levels after rejuvenation (0.4 6 0.1%), with one unit at 1.08%. During the 24-hour storage period after deglycerolization at 1 to 68C in saline/dextrose solution, the mean hemolysis increased to 1.9 6 0.6% (Fig. 1A) . Concentration by centrifugation of the stored RBCs and subsequent removal of the supernatant may be necessary to reduce plasma Hb before transfusion to acceptable levels of hemolysis (<1%), according to the manufacturer's instructions. The hemolysis in these units, assuming the removal of supernatant to a final hematocrit of 85%, was calculated as 0.2 6 0.1%. Spun hematocrit decreased from 64 6 2% on Day 0 to 51 6 2% in rejuvenated units and decreased to 41 6 5% after deglycerolization, primarily reflecting the effects of solution additions during the processing sequence. The calculated percentage in vitro freeze-thaw-wash recoveries were 94.8 6 1.2% (calculated with the total waste Hb content) and 93.8 6 1.5% (calculated using the total Hb content of the final product). Therefore, either approach should be acceptable for this determination. The pH (228C) decline over the 42-day refrigerated storage period was not corrected by rejuvenation, and progressive acidification was observed at each stage with a final value of 6.35 6 0.04. Supernatant potassium concentrations at Day 42 were 61.5 6 6.1 mM (Table 1) . Potassium was reduced with deglycerolization to 1.5 mM and remained low over the 24-hour hold with final values of 2.4 6 0.5 mM. Likewise, supernatant sodium concentrations on Day 42 were 106 6 4 mM and were restored to normal values (156 6 1 mM) after deglycerolization with final values of 152 6 3 mM after 24 hours of refrigerated storage in saline/dextrose. The supernatant osmolality values after deglycerolization in the expected physiologic ranges of 
Metabolomics analyses
In total, 292 biochemical compounds were identified with mass spectrometry-based metabolomics approaches. Observed but unidentified compounds are not reported. After cold storage for 42 days, 181 of these compounds (67%) had a greater than 61.00-fold change (p 0.05) compared with Day 0 (false-discovery rate, q 5 0.0269). After rejuvenation, a total of 167 (57%) of these compounds showed a greater than 61.00-fold change (p 0.05; q 5 0.0299) from Day 42 (Table S1 , available as supporting information in the online version of this paper). PLS-DA analyses of samples distribution on the basis of metabolic phenotypes discriminated an aging/ rejuvenation effect along Principal Component 1, explaining 27.6% of the variance, and a cryopreservation effect along Principal Component 2 (14.1% of the variance) (Fig.  S1 , available as supporting information in the online version of this paper). PLS-DA profiles of Day 0 and rejuvenated RBCs were discriminated by Principal Component 1 and thus were peculiarly distinct. Similar results were observed through hierarchical clustering analysis (Fig. S2 , available as supporting information in the online version of this paper). In Fig. 2 , we show a detail of the heat map focusing on the pathways mostly affected by cold liquid storage for 42 days, rejuvenation, frozen storage and deglycerolization, and final 24-hour storage at 48C (a vectorial version of this figure is provided in Fig. S3 , available as supporting information in the online version of this paper). Pathways include energy and amino acid metabolism, purine metabolism, glutathione homeostasis, the pentose phosphate pathway (PPP), and lipid metabolism (Fig. 2) . Detailed descriptions of the results for the metabolites involved in each of these pathways are provided below (Figs. 3 and 4, Fig. S4 , available as supporting information in the online version of this paper).
Energy metabolism: ATP, DPG, and glycolysis
Storage resulted in the progressive depletion of glycolytic precursors and accumulation of late products pyruvate and lactate (Fig. 3A) . By providing pyruvate, rejuvenation of 42-day-old RBCs not only promoted late glycolysis but also replenished the levels of early precursors (Fig. 3A) . Although progressively lost, the effect of rejuvenation was preserved for hexose phosphates, diphosphoglycerate (as measure by mass spectrometry technologies), and lactate even upon frozen storage and thawing/deglycerolization and 24-hour cold liquid storage (Fig. 3A) . Although storage resulted in significant decreases in the levels of high-energy phosphate compounds, rejuvenation was effective in increasing the ATP and DPG levels ( Table 4 , Fig. 1B,C) . The ATP content in post-Rejuvesol solution-treated RBCs was restored immediately after incubation to 7.9 6 1.4 mmol/g-Hb (97.5% 
Purine metabolism and the PPP
Purine metabolites (Fig. 3B , Table S1 , Fig. S2 ), including adenosine, adenosine monophosphate, inosine, guanine, xanthine, and hypoxanthine, increased during cold liquid storage, consistent with previous reports. 7, 8, 10 The addition of rejuvenation solution, which contains both adenine and inosine, resulted in increased levels of these two metabolites as well as elevations in hypoxanthine, adenosine diphosphate, inosine monophosphate, 6-phosphogluconate (6PGL), ribose-5-phosphate (RIB-5P), pentose phosphates, guanine, and urate (the final product in the purinedegradation pathway), and adenine-containing cofactor NAD1 (Fig. 3B, Table S1 , Fig. S2 ). Hypoxanthine levels of 66 6 29 mM (0.066 6 0.029 mmol/mL) and inosine of 43 6 32 mM (0.0436 0.032 mmol/mL) are comparable to those reported by Valeri and colleagues. 28 Rejuvenation significantly boosted PPP, mostly of the nonoxidative phase branch, although significant increases in 6-phosphogluconate (oxidative branch) were also observed in rejuvenated samples, but not at the other stages (Fig. 3B) .
Glutathione homeostasis and amino acid metabolism
An overview of glutathione homeostasis and amino acid metabolism/transamination reactions is provided in Fig.  4A . Consistent with previous findings, 29, 30 42 days of storage resulted in accumulation of the glutathione precursors cysteine, glycine (Fig. 4B) , and homocysteine (Table S1 ) and recycling/degradation product 5-oxoproline with reductions in reduced glutathione (GSH) and oxidized glutathione (glutathione disulfide [GSSG] ) and the glutathione-like biochemical ophthalmate (Fig. 4C) . Rejuvenation only partially restored the effect of 42-day cold liquid storage on the levels of GSSG and GSH precursors, suggestive of minor increases in glutathione biosynthesis. However, measurable increases (approximately 15%) in GSH levels compared with the levels in 42-day stored RBCs were observed only in frozen/ deglycerolized RBCs and at the final time point. Rejuvenation-dependent normalization of the intracellular level of basic amino acids arginine and lysine, as well as cysteine, leucine/isoleucine, serine, and threonine, are suggestive of an effect of rejuvenation on amino acid transport and, specifically, on band 3-dependent transport, the y 1 L system, and, to some extent, ASC transporter. 9 Consumption of aspartate and generation of fumarate were observed upon rejuvenation, suggesting ongoing salvage reactions. Fumarate theoretically can be generated by urea cycle reactions (Fig. S4A) . Rejuvenation normalized ornithine levels to Day 0 control values upon the increase induced by storage for 42 days. This result is suggestive either of the partial deregulation of a potentially functional cytosolic version of the urea cycle 31 or of ongoing nitric oxide synthesis by RBC endothelial nitric oxide synthase. 28, 32 Accumulation of citrulline upon rejuvenation may underpin the latter hypothesis (Fig. 4A,B) . Accumulation of spermidine and spermine was observed after cold liquid storage or rejuvenation, respectively, despite the absence of polyamine synthesis enzymes in mature RBCs. 33, 34 Thus, fumarate can be metabolized to malate by the cytosolic enzyme fumarase, which has been detected through proteomics in mature RBCs.
31,35
Lipid homeostasis
Rejuvenation promoted a significant accumulation of long-chain fatty acids (e.g., stearate and palmitate) and lysophospholipids, especially lysophosphocholines and lysophosphoethanolamines (Table S1 ). Reductions in levels of the signaling sphingolipid erythro-sphingosine-1-phosphate and ceramide (N-palmitoyl-D-erythro-sphingosine) were observed after 42 days of storage, but significant elevations in these metabolites and the sphinganine precursor 3-ketosphinganine were observed with RBC rejuvenation (Table S1 ). Moreover, significant reductions in these metabolites after freezing and deglycerolization were observed, whereas a 24-hour storage period postdeglycerolization had no additional effects on sphingolipidrelated metabolites.
Effectiveness of the deglycerolization process
Consistent with previous findings, 27,28 the mean cell volume was highest in frozen-thawed RBCs before deglycerolization (129 6 5 fL) (Table 1 ), in line with the highest levels of intracellular glycerol detected through metabolomics (Table S1 ). However, the deglycerolization process was effective, because the osmolality values demonstrated the removal of glycerol to expected physiologic ranges of 303 6 4 mOsm/kg H 2 O, which were similar to the ranges reported by Valeri and colleagues (332-343 mOsm/kg H 2 O).
26,28 
DISCUSSION
In the last few years, the field of transfusion medicine has been split by discussions on the inconsistencies between the myriad of biochemical and morphological lesions occurring during routine storage of RBCs and the reassuring results from randomized clinical trials. 3, 12, 15, 16 It has been noted that little or no knowledge is currently available to conclude whether some of the documented lesions, if any, play an actual role in mediating RBC survival and function and, thus, transfusion safety and efficacy once RBCs get transfused.
12
AABB has recently published a clinical practice guideline that considered current evidence related to the length of RBC storage before transfusion. 34 Based on a review of 13 published clinical trials, they concluded that the transfusion of fresher RBCs was not superior to standard issue practice (i.e., extended storage time) for mortality, with a moderate quality of evidence. For adverse events and infection, they also found that fresher RBCs were not superior to standard of practice RBC age at issue, yet with a low quality of evidence. The additional, panel-recommended trials on the clinical effects of RBC storage duration do not appear to be warranted at this time. Although the results from the randomized trials and the AABB meta-analysis and consensus guideline are welcomed and encouraging, there are still many open questions related to the RBC and transfusion effects. As pointed out by Klein and others, the recent randomized trials were constrained by an inability to randomize to the oldest RBCs available in the blood bank (35-42 days), a storage duration that may represent from 9 to 20% of transfused cells. 4, 35 Despite efforts by many investigators, we are still lacking a sensitive and specific, direct method for measuring the effect of RBC transfusion on oxygenation of tissues in either a patient or an animal model. The effect of longer RBC storage on effective tissue oxygenation has not been thoroughly investigated. At a recent National Institutes of Health and FDA workshop on RBC for transfusion, RBC-associated toxicity was discussed, and data related to potential mechanisms associated with the transfused RBC were presented, suggesting many important areas of future investigation. 36 Finally, there have been no randomized trials evaluating metabolically modified RBCs. Therefore, although current clinical evidence gives us some assurance in continuing the current standard of care with respect to RBC storage duration, there is still much to be learned about the mechanisms and effects of transfused RBCs on patients. The data we present in this study shed important light on metabolic effects of storage and the biochemical rejuvenation of stored RBCs. Of all the metabolic lesions RBCs suffer during cold liquid storage, 37 it has been suggested that depletion of the high-energy phosphate compounds ATP and DPG is reversible, although delayed, upon transfusion into recipients. 18 In this view, research-mostly carried out by
Valeri and colleagues over the last 30 years-has aimed at restoring at least these relevant parameters even before transfusion, through the supplementation of fresh substrates, a process referred to as rejuvenation. . ATP and DPG depletion during storage was previously attributed to deregulated glycolysis during refrigerated and frozen storage of RBCs. Here, we focused on the effect of rejuvenation and cryopreservation/thawing/deglycerolization and 24-hour cold storage on glycolytic metabolism and ATP and DPG generation. Rejuvenation effectively restored ATP and DPG reservoirs, which were preserved during subsequent frozen storage and 24-hour final refrigerated storage. Because only steady-state levels of metabolites in the glycolytic pathway were monitored, it cannot be ruled out whether supplementation of pyruvate in the rejuvenation solution promoted gluconeogenesis-like, reductive fluxes toward the generation of hexoses or inhibition of forward oxidative reaction of glycolytic enzymes, on the basis of the mass action law. However, the recovery of ATP and DPG suggests that the latter hypothesis can be ruled out.
Notably, previous reports suggest that total NAD 1 / NADH reservoirs may plummet during storage and nicotinamide may accumulate, thereby depriving glycolytic enzymes of a rate-limiting cofactor. 9 Rejuvenation of purines through supplementation of adenine also boosted NAD 1 levels, providing an alternative explanation for the restored glycolytic rate and ATP/DPG generation upon rejuvenation. Supplementation of excess pyruvate would also promote oxidation of NADH back to NAD 1 by favoring forward reactions to lactate by lactate dehydrogenase. The purine base adenine is included in both RBC storage and rejuvenation solutions for the purpose of maintaining cellular ATP by providing a substrate for salvage reactions. Long-term storage of RBCs was indeed associated with depletion of adenine and a corresponding increase in other purine-related metabolites, as previously reported. [7] [8] [9] 11, 39, 40 Most of these anomalies in purine metabolism were corrected by rejuvenation.
The rejuvenation solution also contains inosine, which is a precursor to inosine monophosphate that, in turn, can be salvaged to adenosine monophosphate by adenylosuccinate lyase, which is present in RBCs. 31 Activity of this enzyme requires aspartate and generates fumarate, which indeed are consumed and normalized to Day 0 levels, respectively, upon rejuvenation. Inosine can alternatively undergo pyrophosphoribolysis, thereby releasing ribose phosphate to fuel the nonoxidative branch of the PPP and hypoxanthine. Fueling of salvage reactions by inosine breakdown promotes an ATP generation step without initial energy expenditure, as pentose phosphates reenter late glycolysis. Of note, here, we observe an increase of oxidative phase PPP intermediates (6-phosphogluconate). To the authors' knowledge, fluxes from the nonoxidative to the oxidative PPP branches are not possible. Although mass action blockade of phosphoglucoante dehydrogenase activity due to the accumulation of pentose phosphate products may be a plausible explanation, the increased levels of hexose phosphate glycolytic precursors and the restoration of GSH and GSSG levels observed upon rejuvenation are suggestive of an ongoing NAD phosphate-generating PPP, an antioxidant pathway that is progressively deregulated during routine refrigerated storage.
9,41
The inosine breakdown product hypoxanthine is typically metabolized by the enzyme xanthine oxidase, releasing hydrogen peroxide in the process. However, RBCs lack xanthine oxidase; therefore, increased hypoxanthine in stored RBCs can have negative consequences for a transfusion recipient. Both storage [4] [5] [6] [7] [8] [9] [10] 39 and rejuvenation of RBCs result in hypoxanthine accumulation, which nevertheless is washed out during processing for freezing and deglycerolization. A small build-up of hypoxanthine is again initiated with an additional 24-hour refrigerated storage post-deglycerolization. An excess of pyruvate, supplemented through rejuvenation, may promote transaminase activity to generate alanine or oxaloacetate accumulation by pyruvate carboxylase. 42 The storage-dependent accumulation of alanine 44 Although activity of the key lysophosphatidylcholine acyltransferase enzymes is weak in mature RBCs, 45 1-acylglycerol-3-phosphate O-acyltransferase has been detected through proteomics technologies. 31 This pathway transiently generates lysophospholipid before restoring phospholipid homeostasis and thus membrane structural properties and functional dynamics (e.g., spontaneous curvature and bending elasticity). 46 We note that alterations in free fatty acids, long-chain acylcarnitines, glycerolipids, lysolipids, and the phospholipid-signaling metabolite inositol 2-phosphate were observed upon rejuvenation of RBCs, providing support for the notion of an at least partial reversibility of the storage lesion to RBC membranes. Here, we show for the first time that rejuvenation of 42-day-old RBCs does not just replenish ATP and DPG, but it does promote significant systemic metabolic reprogramming within the stored RBCs. These effects include the reactivation of energy-generating and anti-oxidant pathways (PPP and glutathione homeostasis) as well as salvage reactions, cofactor reservoirs, and membrane lipid recycling. Despite the effects on metabolism, rejuvenation of RBCs stored for 42 days may be less effective or simply too late of an actor to prevent or correct the previously documented "irreversible storage lesions," such as the acquisition of spheroechinocytic and spherocytic morphologies, the irreversible oxidation and fragmentation of proteins and lipids, the disappearance of CD47 ("do not eat me signal"), impairment in iron homeostasis, the extensive vesiculation events, and the activation of caspase-involving, apoptosis-like cascades. 47, 48 However, further metabolomics studies are needed to determine whether these "irreversible storage lesions" can be altered with rejuvenation if RBCs are stored for less than 42 days. Finally, it emerges that metabolic control (alternative additives/storage strategies) and rejuvenation of refrigerated RBCs offer yet underexplored avenues to improve RBC storage quality and potentially extend storage duration for precious blood units, such as those from rare blood group donors, as inventory management strategies continue to evolve. 
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